Connect Biopharma Holdings Limited CNTB
Sector:
HealthcareIndustry:
BiotechnologyDescription:
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.Recent Quarter:
2024-09-05Upcoming Quarter:
N/AAnnual Reports
Date2024-04-16
Revenue 0
Net Income -59,503,000
EPS -1.08
Basic Shares 55,067,021
Diluted Shares 55,067,000
Report Link
Date2023-04-11
Revenue 0
Net Income -116,415,196
EPS -14.5
Basic Shares 55,044,000
Diluted Shares 55,044,000
Report Link
Date2022-03-31
Revenue 0
Net Income -205,205,345
EPS -25
Basic Shares 52,272,960
Diluted Shares 52,272,960
Report Link
Date2020-12-31
Revenue 0
Net Income -120,303,936
EPS -14.45
Basic Shares 53,941,675
Diluted Shares 53,941,675
Report Link
Date2019-12-31
Revenue 0
Net Income -24,021,147
EPS -3.02
Basic Shares 55,816,675
Diluted Shares 55,816,675
Report Link
Annual Ratios
Date2023-12-31
PE -1.09
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -0.41
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -1.31
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -8.29
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-12-31
PE -42.96
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2018-12-31
PE 0.00
Dividend Yield 0.00
Payout Ratio: 0.000%
Quarterly Reports
Date2024-06-30
Revenue 12,058,000
Net Income 3,824,500
EPS 0.0694
Basic Shares 55,143,825
Diluted Shares 55,554,249
Report Link
Date2024-03-31
Revenue 12,058,000
Net Income 3,824,500
EPS 0.0694
Basic Shares 55,143,825
Diluted Shares 55,554,249
Report Link
Date2024-04-16
Revenue 0
Net Income -14,805.583
EPS -0.27
Basic Shares 55,082,000
Diluted Shares 55,082,000
Report Link
Date2023-09-30
Revenue 0
Net Income -15,226.927
EPS -0.28
Basic Shares 55,082,000
Diluted Shares 55,082,000
Report Link
Date2023-06-30
Revenue 0
Net Income -30,581,163
EPS -0.56
Basic Shares 55,051,351
Diluted Shares 55,051,351
Report Link
Date2023-03-31
Revenue 0
Net Income -15,431.8,830,411
EPS -0.28
Basic Shares 55,051,000
Diluted Shares 55,051,000
Report Link
Date2023-04-11
Revenue 0
Net Income -56,678,631
EPS -1.03
Basic Shares 55,022,777
Diluted Shares 55,022,777
Report Link
Date2022-09-30
Revenue 0
Net Income -30,843.077
EPS -0.56
Basic Shares 55,023,000
Diluted Shares 55,023,000
Report Link
Date2022-06-30
Revenue 0
Net Income -61,918,783
EPS -1.12
Basic Shares 55,064,947
Diluted Shares 55,064,947
Report Link
Date2022-03-31
Revenue 0
Net Income -31,643.7,718,767
EPS -0.57
Basic Shares 55,064,000
Diluted Shares 55,064,000
Report Link
Date2022-03-31
Revenue 0
Net Income -56,652,416
EPS -1.05
Basic Shares 53,735,021
Diluted Shares 53,735,021
Report Link
Date2021-08-31
Revenue 0
Net Income -28,248.899,024
EPS -0.49
Basic Shares 57,418,000
Diluted Shares 57,418,000
Report Link
Date2021-08-31
Revenue 0
Net Income -145,709,216
EPS -3.1
Basic Shares 46,935,542
Diluted Shares 46,935,542
Report Link
Date2021-03-31
Revenue 0
Net Income -71,917.6,650,156
EPS -1.53
Basic Shares 46,935,000
Diluted Shares 46,935,000
Report Link
Date2020-12-31
Revenue 0
Net Income -53,924.599,419,499,995
EPS -3.16
Basic Shares 17,089,000
Diluted Shares 17,089,000
Report Link
Date2020-09-30
Revenue 0
Net Income -51,841.5,045,311
EPS -3.03
Basic Shares 17,089,000
Diluted Shares 17,089,000
Report Link
Date2020-06-30
Revenue 0
Net Income -5,322.1,286,523
EPS -0.31
Basic Shares 17,090,000
Diluted Shares 17,090,000
Report Link
Date2020-03-31
Revenue 0
Net Income -5,309.3,540,402
EPS -0.31
Basic Shares 17,090,000
Diluted Shares 17,090,000
Report Link
Quarterly Ratios
Date2024-06-30
PE 5.19
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2024-03-31
PE 7.93
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-12-31
PE -1097.50
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-09-30
PE -740.66
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-06-30
PE -0.51
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-03-31
PE -891.84
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -0.21
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-09-30
PE -575.33
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-06-30
PE -0.19
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-03-31
PE -1313.79
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -1.22
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-09-30
PE -12312.32
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-06-30
PE -1.57
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-03-31
PE -3018.37
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -1464.90
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-09-30
PE -1523.76
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-06-30
PE -14843.41
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-03-31
PE -14879.12
Dividend Yield 0.00
Payout Ratio: 0.000%
RSI:
49.94Price:
$1.15Market Cap:
63,542,137EPS TTM:
-0.41PE Ratio:
8.11PEPSG:
NaNFwd PE:
NaNVolume:
27,1932 Year Price Change
1.333Index 2 Year Price Change
1.5065 Year Price Change
No Price 5 Years AgoIndex 5 Year Price Change
1.909PESPG: Growth Rate of EPS projected to next quarter and 6 months trailing. Lower is better to help calculate nexts quarters PE Ratio today. Diluted shares effects the EPS reported and makes calculation show as extremely poor expected growth.
Revenue
Net Income
EPS
Shares
News
Press Releases
Notable Earnings
Please select an option: